Chinese Experts Issue New Prolactinoma Treatment Guidelines

Sixty specialists in China developed and released new guidelines for diagnosing and managing prolactinomas, benign pituitary tumors, with the goal of improving patient care. The consensus integrates the latest evidence and clinical expertise into 36 recommendations, emphasizing early detection through serum prolactin assays and advanced MRI imaging. These guidelines address challenges like macroprolactinemia and the Hook effect, advocating for genetic testing and tailored treatment plans.

The recommendations extend to specific populations including pregnant women and men, and offer pathways for treating prolactinomas resistant to standard dopamine agonists. Professor Sheyu Li, the lead author, noted the guidelines promote a patient-centered, collaborative approach.

The new framework aims to standardize care, increase diagnostic accuracy, and improve outcomes for patients with prolactinomas, which commonly cause menstrual irregularities, infertility, and visual disturbances. Researchers hope these guidelines will also stimulate further research into the condition.